written by reader Discussion page for Arch Therapeutics (ARTH)

By Lynn Clark, Stock Gumshoe, November 6, 2017

This page is for discussion of Arch Therapeutics (ARTH).

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

772
Share your thoughts...

avatar
186 Comment threads
586 Thread replies
0 Followers
 
Most reacted comment
Hottest comment thread
138 Comment authors
blackngold63blackngold63deanbobfinventurerfrankw17 Recent comment authors

This site uses Akismet to reduce spam. Learn how your comment data is processed.

analog68
Irregular
👍389
analog68

Love Cleveland financial info. Awesome to see you again!

omcdac1
Member
👍468
omcdac1

Cleveland – Welcome back my friend.

Cleveland
Irregular
👍6053

$ARTH New Theme: “Dr. KSS program to make Stock Gumshoe great again: Arbitrarily kick people out of Biopubkss” From this forum: “I can tell you from my perspective as someone whose PhD was in clotting biochemistry, I am sure AC5 will work in humans.” A variation on JohnM’s great statement: “It’s a shame that the man whose PHD was in clotting biochemistry and who found $ARTH as an investment and vetted the technology won’t benefit from what might be the biggest winner he ever recommended.” ARTH Market Cap today $66.319 Capital raised by ARTH since its inception $ 32.594 million… Read More »

Add a Topic
3932
Add a Topic
5971
Add a Topic
3932
savethemanatee
Irregular
👍2289
savethemanatee

My impression is that many folks are focused on the expense side of the equation: If $ARTH (or any clinical-stage biotech) spends money, it will bring the ratio down. Lengthy trials cost boatloads of money. Therefore, the Cleveland ratio is meaningless for companies involved in complicated research. This confuses (what I think is) your point. What your ratio does is compare money spent to how the market values those expenditures and efforts. In that way it is very clever. Here is an analogy. My neighbor (who is a total jerk and preoccupied on his image, but I digress) buys a… Read More »

Add a Topic
1340
Cleveland
Irregular
👍6053

STM I am working on several projects and will get back to this. My computer screens focus on this now. Thanks.

Cleveland
Irregular
👍6053

$DMCAF STROKE DiaMedica Therapeutics Like $ARTH I believe $DMCAF is a derisked situation that I believe there could be a early exit by selling the company to Big Pharma. I had a couple conference calls with Doc and management. Management is excellent. See my capital analysis. Company intends to do reverse split during 2018 but I believe they will time it with some positive news events.  It trades tightly.  See the Capital analysis and other reports. Cleveland Capital Analysis  https://www.dropbox.com/s/cerrnteddcs8fid/Capital.xlsx?dl=0 Zacks Initiation Report  https://www.dropbox.com/s/tbn3jej5luof0me/DiaMedica%20Initiation%20Report%20Zacksvery.docx?dl=0 Patrick Cox Email DMCAF—John Mauldin Investor  https://www.dropbox.com/s/fsq7ezofqcffeqk/Full%20Patrick%20Cox%20Article%20t.docx?dl=0 Sale of Competitor Product establishing Value for DMCAF  https://www.dropbox.com/s/rm45kswle46q9th/DMA%20Sale%20of.docx?dl=0… Read More »

Add a Topic
665
Add a Topic
951
Add a Topic
665
Cleveland
Irregular
👍6053

$DMCAF Here are come changes. Most important is the Cleveland Capital Analysis. which was update to 3/31/18—-

Capital —Note upside potential

https://www.dropbox.com/s/jyr9r6x0g9nd9gu/DIAMEDICA%20GOOD%20Capital%203%2031%202018-%20Copy.xlsx?dl=0

Sale–Techpool Bio-pharma sale and impact on DMCAF

https://www.dropbox.com/s/pr599ei459syb9o/DMCAF%20Sale%20of.docx?dl=0

Add a Topic
1278
JohnM
Irregular
👍1992

$DMCAF, wow, Cleveland, great stuff! There goes my weekend…DD time.

Cleveland
Irregular
👍6053

JohnM

This is right up your alley for picks. IMHO there will be early exit by Big Pharma buyout. How soon? CEO Rick Pauls is the person to talk with.

John Mauldin in the deal does not hurt !

Add a Topic
2931
richardo8586
Member
👍510
richardo8586

Sigh, you and Doc did make a good team

Cleveland
Irregular
👍6053

Agree. But lying and slandering me is plain WRONG. All to improve your own self image? “Ardelyx once interested me, but Cleveland saved our collective backside as the quants were unsound.” “I think it’s horrifying Cleveland got caught in the crossfire on this one and called a liar. Cleveland is a man of extreme integrity and insight who is here to shine light on situations, and he is indispensable.” “Cleveland’s posts are of great moment, valuable to all, and I’d prefer to see them in the forum.” Eyedoc “I want to thank Cleveland for contributing to a life-altering change in… Read More »

richardo8586
Member
👍510
richardo8586

Well Cleveland, sh*t hits the fan so fertilizer can rain. Your comments are helping to make things grow . Much appreciated

Add a Topic
2368
Cleveland
Irregular
👍6053

$ARTH Arch Therapeutics CEO looks ahead to positive results on AC5 gel

http://tinyurl.com/ydco3az3

“It’s a shame that the man whose PHD was in clotting biochemistry and who found $ARTH as an investment and vetted the technology won’t benefit from what might be the biggest winner he ever recommended.”

edinle
Member
👍225
edinle

$CLRBZ
Cleveland, good to see you posting again. I’m wondering if your thinking has changed about CLRBZ warrants. You made a compelling case for them in the past, though they’re worth little now. Cellectar says they’re funded into 2019 Q1, but the last 10Q did not sound confident about raising funds necessary to continue beyond that time. Is this company about to go belly up? I have a basket of Z warrants and am wondering whether to salvage what I can…

Add a Topic
3229
Add a Topic
3229
denton
Irregular
👍398
denton

$ARTH long and certainly enjoying today’s improving stock price…

v/r
jdd

Add a Topic
5971
blackngold63
Irregular
👍170
blackngold63

Yes… Quite nice. Certainly won’t go up like this every day…. but it was definitely under valued. The Good Times are starting to Roll.

Add a Topic
5916
dunnydame
Irregular
👍1106
dunnydame

$ARTH long
Amen, jdd.

mobilecc
Irregular
👍80

Sure glad I had faith (although I’m normally not very religious). Been buying $ARTH all the way down – even got some at 26cents. Maybe too soon to buy champagne but it sure feels good.

mgm0901
Irregular
👍15
mgm0901

Today’s announcement doesn’t look good for us $ARTH shareholders. Appears today’s announcement selling another 9M shares at .50 will be dilutive to our current holdings. Positive PR… company sells new shares into the bump… current shareholders get the dilutive shaft… rinse/repeat.

Add a Topic
4393
Add a Topic
4393
Add a Topic
4393
J_M_Banks44
Irregular
👍130
J_M_Banks44

https://ir.archtherapeutics.com/press-releases/detail/509 $ARTH – “today announced the pricing of registered direct offering of 9.1 million units, each unit consisting of a share of the Company’s common stock, and a Series G Warrant (“Series G Warrant”) to purchase 0.75 of a share of our common stock for the combined purchase price of $0.50 per unit. The Series G Warrants have an exercise price of $0.70 per share and are exercisable for a period of five years. The gross proceeds to Arch from this offering are approximately $4.5 million before deducting estimated offering expenses payable by the Company. The offering is expected to… Read More »

Add a Topic
5971
Add a Topic
5971
Add a Topic
3229
mgm0901
Irregular
👍15
mgm0901

Possible re-entry at .27?

J_M_Banks44
Irregular
👍130
J_M_Banks44

Pure speculation, but I highly doubt it will dip that low. Gut reaction is that it will ride around the .45 mark here for a while until an update on the study comes out.

mgm0901
Irregular
👍15
mgm0901

Hopefully you’re right but if we see a close below .46, there’s some support at .36 albeit weak. I still believe we could see a touch of the longer-term support in the .26 to .27 range over the next 6-8 weeks – then a nice ramp if they don’t have to go back to the well before October. If, on the other hand, support holds at .47 and we close with volume, could be a nice low risk entry.

JohnM
Irregular
👍1992

$ARTH long What do you mean by “if they don’t have to go back to the well before October”?

JoeS
Irregular
👍1768
JoeS

John,

Do you have any thoughts on what occurred yesterday?

Thx- Joe

JohnM
Irregular
👍1992

I worry a lot more about biotech companies that can’t raise money than those that can. This $4.5 million will carry ARTH into the December 2019 quarter, so we will get the results of the sensitization study, the 510(k) filing, the CE Mark filing, the 510(k) approval, the CE Mark approval, and the IND filing for internal use before he needs to raise money again. Actually, I expect him to sign a distribution deal in 2019, if only for Europe, that should provide enough upfront cash to avoid any more stock sales. Norchi has an MBA and ran Putnam’s healthcare… Read More »

Add a Topic
5971
Add a Topic
229
Add a Topic
5971
mgm0901
Irregular
👍15
mgm0901

If the current raise is enough to carry them through until their next FDA submission.

Add a Topic
3022
JohnM
Irregular
👍1992

Do you mean the October 2018 submission? Norchi only burns $1.3 million a quarter and said before the raise that he had enough money to get into the December quarter. He now has enough to get through the September 2019 quarter. Why on earth would he have to “go back to the well” so soon after doing a large capital raise?

mgm0901
Irregular
👍15
mgm0901

Thanks for your insight John – invaluable perspective and I can tell BioPharma is your ballpark. I’m learning much reading through your well appreciated thesis. I missed that they raised enough to carry into the Dec QTR – thanks! Many herein see technical analysis synonymous with the reading of tea leaves but I believe that psychological and Algo buy/sell points are entwined with price action/momentum for higher probability market direction. I’m overall bullish $ARTH, but believe we’re do for a pullback to prior support at .37 and possibly .27 respectively if we don’t see a break soon through the strong… Read More »

SoGiAm
Irregular
👍11474

Nerve damage caused by traumatic injury could better heal with hydrogel that is 15 times stronger than currently available wound sealants. https://news.northeastern.edu/2018/06/27/hydrogel-could-regenerate-stronger-healthier-nerves-in-injured-soldiers/? TY https://news.northeastern.edu/wp-content/uploads/2018/06/koppes_1400 .jpg

Photocrosslinkable Gelatin/Tropoelastin Hydrogel Adhesives for Peripheral Nerve Repair
Soucy Jonathan R. , Shirzaei Sani Ehsan , Portillo Lara Roberto , Diaz David , Dias Felipe , Weiss Anthony S. , Koppes Abigail N. , Koppes Ryan A. , and Annabi Nasim #MeTro 🙂
Published Online:9 May 2018 https://doi.org/10.1089/ten.tea.2017.0502

Griffin
Irregular
👍3618